BioSpace News Archive

Heart Health Intelligence has joined the American Heart Association’s Center for Health Technology & Innovation’s Innovators’ Network. The Center is focused on building and fostering health tech relationships to develop innovative and scalable solutions. Innovators’ Network members have access to the Association’s digital guidelines, recommendations, and best-in-class science as they develop various digital healthcare technologies.

OKYO is pleased to announce that it has raised £3,500,000 through the issue of convertible loan notes. The proceeds of the CLNs will be used for working capital purposes as detailed below.

Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates

Participation from top-tier healthcare investors recognizes momentum across breadth of its CNS therapeutics portfolio

Santen Pharmaceutical Co., Ltd and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc, announced an exclusive license agreement covering the development, registration, and commercialization rights in Japan, China, and other Asian countries as well as EMEA countries

Ortho Regenerative Technologies Inc., an emerging orthobiologics company, announced new positive results following completion of its pivotal preclinical study report in Rotator Cuff Tear repair under Good Laboratory Practices conditions.

Abzena, a leading global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates, has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm.

Scholarships Awarded to Nine Students Affected by Dermatologic Conditions

Up to $13.3M funding to accelerate development and early clinical testing of antibodies derived from large-scale B cell interrogation of COVID-19 “Super-Responders”

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2020 after the U.S.